Insights Into Acute Myeloid Leukemia (AML)

Perspectives on management of newly diagnosed and relapsed/refractory AML

Elias Jabbour MD Anderson Cancer Center Aptitude Health

Meeting Chair

Elias Jabbour, MD

The University of Texas MD Anderson Cancer Center, Houston, TX, USA

Look Inside This Report

Download a sample of this report and start discovering the insights

Report Snapshot

Insights on the following AML therapies were obtained

  • azacitidine
  • cytarabine and daunorubicin (ie, 7+3)
  • decitabine
  • ivosidenib
  • enasidenib
  • gemtuzumab ozogamicin
  • gilteritinib
  • liposomal daunorubicin and cytarabine
  • midostaurin
  • sorafenib
  • venetoclax
  • glasdegib

GEOGRAPHIC REPRESENTATION & CONTENT DEVELOPMENT

  • A moderated roundtable discussion focusing on treatment of AML was held on October 26, 2019, in Seattle, WA
  • Disease state and data presentations were developed in conjunction with a medical expert from UC Davis
  • The group of advisors comprised 10 community oncologists
  • Data collection was accomplished through use of audience response system questioning and in-depth moderated discussion

Explore Available and Upcoming Insight Reports

View Reports